Freedom Broker raises Eli Lilly stock price target on GLP-1 demand

Freedom Broker raised its Eli Lilly price target to $1,600 from $1,400 and maintained a Buy rating, citing strong demand for GLP-1 therapies and a strong commercial start for oral Foundayo. Lilly reported Q3 2026 revenue of $24.4B, about $1.9B above consensus, and raised full-year guidance to $91B–$92B, nearly $10B above its initial outlook. Multiple other firms also raised price targets, while the article reports revenue growth of 45.5% over the last 12 months.

Analysis

The earnings reset strengthens the near-term fundamental floor, but the incremental trade is less compelling than the headline growth suggests: LLY has already risen 64% over the past year, and the cited $1,600 target is about 13% above the supplied share price. That is not a risk-adjusted return estimate; downside could be asymmetric if expectations for continued rapid growth are embedded in the price. Multiple target increases are not independent evidence of future demand and may partly follow the same guidance surprise.

Over days, momentum can persist as estimates catch up. Over 1–3 months, the key tests are whether prescription growth converts into realized revenue and whether management sustains its outlook; track reported volume, net pricing, supply availability, and any guidance changes. Over 6–18 months, oral Foundayo could broaden access and the treated market, but could also shift demand from injectable products or increase price competition. Broader access only creates value if reimbursement and manufacturing support profitable volume. Verify these details rather than extrapolating the launch description or nonincretin performance.

The contrarian risk is not that demand has disappeared, but that investors extrapolate unusually strong growth without enough attention to affordability, payer coverage, capacity, and competitive responses, including Novo Nordisk. A guidance cut, weaker-than-expected prescription-to-sales conversion, deteriorating net pricing, or supply constraints would falsify the bullish continuation thesis. No justified valuation-based short is available from the supplied data.

Key Decisions for Investors

• Avoid chasing the post-results move. Treat the roughly 13% gap from the current quote to Freedom Broker’s target as limited stated upside, not a valuation floor; reassess after estimates and price action settle.
• For existing LLY exposure, retain only while revenue delivery and full-year guidance remain intact. Set an alert for guidance reductions, slowing volume, or evidence that net pricing is offsetting prescription growth.
• Watch the next 1–3 months of prescription, reimbursement, and supply disclosures for Foundayo. If oral uptake expands total treated demand without materially displacing injectable sales or pressuring realized prices, that supports adding on consolidation; if substitution or price concessions dominate, reduce exposure.
• Do not initiate a peer pair trade solely on this article. Compare LLY and Novo Nordisk on verified prescription trends, net pricing, capacity, and forward estimates before positioning.